Our products empower healthcare professionals and improve potential outcomes by aiding in the early diagnosis of oral cancer (including oral and oropharyngeal cancer).
Vigilant Biosciences® products are based on advanced patented technology, including an innovative methodology for measuring total protein levels and assessing the level of tumor-initiating and stem cell-associated biomarker CD44 that, together with other clinical factors, can aid clinicians in the early detection and intervention of oral cancer. These clinically validated tests enable early and accurate detection of oral cancer, potentially even before visual or physical indicators.
This foundational science leverages nearly two decades of clinical research conducted by Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
